- 英文名称
- N-((2S,3S,4R)-3,4-Dihydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)hexacosanamide
- 分子式
- C50H99NO9
- 分子量
- 858.32
- 中文别名
- (2S,3S,4R)-1-O-(α-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol; alpha-Galactosylceramide; alpha-GalCer; alpha-Galactosyl Ceramide; DTXSID40935847; CHEBI:466659; WX671898JF; RGI-7000; a-GalCer; CHEBI:132148; N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]hexacosanamide; N-((2S,3S,4R)-3,4-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxyoctadecan-2-yl)hexacosanamide; Alpha Galactosylceramide; RefChem:794363; DTXCID601766457; 973-258-3; KRN7000; Krn 7000; Krn-7000; .alpha.-galcer; CCRIS 8968; MFCD00939559; AGL-582; Galalpha-Cer(t18:0/26:0); 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine; N-((2S,3S,4R)-3,4-dihydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)hexacosanamide; 1-O-(alpha-D-galactopyranosyl)-N-hexacosanoylphytosphingosine; N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]hexacosanamide; N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE; α-D-Galactosylceramide; C50H99NO9; (2S,3S,4R)-1-O-(alpha-D-galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol; -Galactosylceramide; a-Gal-Cer; A-GALACTOSYLCERAMIDE; UNII-WX671898JF; VQFKFAKEUMHBLV-BYSUZVQFSA-N; RGI-2001; ??-Galactosylceramide; α-D-Galactosyl Ceramide; alpha-GC(C26); alpha-GC (C26); -GalCer; KRN7000; Epitope ID:130694; Epitope ID:738312; SCHEMBL512949; CHEMBL384200; orb1707685; alpha-GalCer(t18:0/26:0); CHEMID158021477; GLXC-20229; GLXC-26234; EX-A5755; AKOS040741093; DB12232; MG15978; AC-31508; DA-49185; NS00073040; C16892; T14193; Q27105159; N-[(1S,2S,3R)-1-[(a-D-Galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]hexacosanamide; (2S,3S,4R)-1-O-(alpha-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol, >=95% (TLC); HEXACOSANAMIDE, N-((1S,2S,3R)-1-((.ALPHA.-D-GALACTOPYRANOSYLOXY)METHYL)-2,3-DIHYDROXYHEPTADECYL)-; Hexacosanamide, N-(1-((alpha-D-galactopyranosyloxy)methyl)-2,3-dihdyroxyheptadecyl)-, (1S-(1R*,2R*,3S*))-; hexacosanamide, N-[(1S,2S,3R)-1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]-; Hexacosanamide, N-[(1S,2S,3R)-1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]- (9CI); Hexacosanamide, N-[1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]-, [1S-(1R*,2R*,3S*)]-; N-((2S,3S,4R)-3,4-dihydroxy-1-(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)octadecan-2-yl)hexaicosanamide; N-[(1S,2S,3R)-2,3-dihydroxy-1-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]heptadecyl]hexacosanamide
- 用途
- 主要用于实验室有机合成中和化工医药研发过程中，在小鼠的传染性和自身免疫性疾病中显示出免疫学作用。作为α-Galactosylceramide（α-GalCer），是一种合成的糖脂，具有抗肿瘤和免疫刺激作用，是非常有效的NKT细胞激动剂，可与CD1d有效结合，其复合物可与NKT细胞的T细胞抗原受体结合。体外研究显示其激活的Vα24+NKT细胞培养上清液对黑色素瘤细胞有抗增殖活性，主要由IFN-γ释放引起；体内研究表明其可预防小鼠原发性肿瘤形成及B16黑色素瘤转移，且被认为是一种非特异性免疫刺激剂（生物反应调节剂）。
